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EARLY POSTOPERATIVE COMPLICATION3 DETECTED BY TRAWSESOPEA- 
GEAZ, ECgOCARIXCOGRAPNY IN CARDIOTHORACIC SURGERY PATIENTS. 
Vieto‘ C,bvila-Roman MD,Benico Barzilai MD,Hark Eaton 
MD,Thomas Eemcholas T.Rouchoukos MD,Washington 
University, St. Iouis, MO 
With the advent of highly sophisticated operative 
Drocedures eg.ventricular assist devices(VAD),heart &/or 
iung transpl&s,it becomes more difficult to assess 
cardiac function in the early postoperative(postop) period --~ 
with transthoracic echocardiography(TTE).We report our 
experience during a 9 month period of post cardiothoracic 
surgery pts that developed significant hemodynamic 
alterationa(shock,hypotension,pulmonary edema,diminished 
cardiac output,elevated right sided pressurea)early(l-72 
hours) in their postop period. A total of 68 TTE were 
performed during- this period. Transesophageal 
echocardionranhy(TEE)wae performed in 29 pte due to -- 
nondlagno&c~T?E:l9/29 studies revealed a problem 
requiring surgical intervention(l6 pta had a surgical 
procedure,2 pts died prior to reoperation,l pt surgery was 
not performed);the other 10 pta we documented nonsurgical 
problems. TEE findings were:severe RV dysfunction in 2 
pts,l required inaertion of RVAD;jevere LV dysfunction in 
3 pts which required inaertion of LVAD;severe 
biventricular failure in 6 pts,S of which required 
insertion of right and left VAD;pulmonary venous 
obstruction at the auastomosis site of a single lung 
transplant requiring reanaatomosis;atrioventricular 
rupture post mitral valve replacement requiring 
reexploration;perivalvular leak in 1 pt requiring 
resuturing of the prosthetic mitral valve;superior vena 
cava obstruction and RV failure in 1 pt. ThusI in postop 
cardiac surgical pts with significant alterations TEE 
identified surgically remediable causes which were 
undetected by TTE. 
CONTINUOUS RADIONUCLIDE MONITORING OF LEFT VENTRICULAR 
SYSTOLIC PERFORMANCE IN POSTOPERATIVE CARDIAC SURGERY 
PATIENTS: VALIDATION OF THE CAPINTEC VEST. 
John A. Carey, F.R.C.S.I., James R. Stewart, M.D., Walter 
H. Merrill, M.D., Martin Sam.D., James Atkinson, 
M.D., John W. Hammon, Jr., M.D., William H. Frist, M.D., 
Harvey W. Bender, Jr., M.D.. Vanderbilt Hospital, 
Nashville, Tennessee. 
Clinical evaluation of alternative methods of intraoper- 
ative myocardial protection has been hampered by the 
limited ability to continuously monitor LV performance in 
the early postoperative p riod. We investigated the suit- 
ability and accuracy of a non-imaging nuclear device 
(Capintec VEST) in this setting. 23 consecutive patients 
under 
years B
oing coronary revascularization (mean age 63 + 9.3 
had preoperative LV ejection fractions 49 + T6.1%. 
All patients had pulmonary artery catheters and 23 
patients had LV micromanometer-tipped 5F Millar catheters 
positioned at the time surgery. Following stabilization 
in the recovery room, the VEST was accurately positioned 
with the aid of a standard portable gamma camera. VEST 
determinations of ejection fractions were correlated with 
portable MUGA scans at the commencement and termination of 
the study period. Continuous beat-to-beat time activity 
curves were recorded over 6 hours and cardiac hemodynamic 
parameters over 24 hours. The VEST did not interfere with 
routine ~osto~e~atiwe 
portable ga 
patient car 
camera was good (r=0.89 
SEE=13.23%, n=12). LV ejection fracti 
tively, reaching a nadir 7 hours following myocardial re- 
perfusion, and then gradually returned to normal. The 
VEST can accurately measure LV ejection fractions ;ld may 
have a valuable role in future clinical investigation f
intraoperative myocardial protection. 
EFFICACY OF RECOMBINANT WIRUD 
DUG CARDIOPULMONARY B PASS 
Walenga , H. Bakhos. H.L. 
IN A 
J.M. 
yola 
Unive&y Medical center, Maywood, IL. USA. 
Heparin, the commonly employed anticoagulant for 
cardiopulmonary bypass (CPB) devices, can produce throm- 
bocytopenia and arterial thrombosis necessitating the use 
of -an alternate anticoaaulant devoid of these adverse 
actions. Recombinant h:rudin is a thrombin specific 
inhibitor composed of 65 amino acids and is currently 
produced using E. coli, S. cerevisiae and B. subtlis 
fermentation. We have studied the efficacy of this anti- 
coagulant in CPB. In 10 mongrel dogs an- iv bolus of 1 
??g/kg r-hirudin was administered twice, immediately 
to placing on bypass for 60 minutes and 30 minutes 
rior 
after 
the-first %njec&n. Blood samples and bleeding times were 
per~odi~a~~y after a~t~coag~Iation. No 
antagonist was used to reverse the anticoagulant effect. 
The dogs remained 
bypass .- 
anaesthetixed for 180 minutes post 
Routine (PT, APTT, TT, ACT) and other (calc&un- 
TT, Heptest, Heptest-Hi , anti-IIa) coagulation parameters 
were markedly elevated and bleeding times were >15 min. 
during bypass but all returned to normal within 30 min. 
after- bypass. Other parameters such as hematocrit, 
platelet count and fibrinonen showed an initial decrease 
hue to Plemodilution but no-further change during bypass. 
No clots were observed in the pump filter or tubings. No 
microthrombi were observed by- his tologic exam of heart, 
lung, liver and kidney. These data are similar to those 
obtained in 20 mongrel dogs in the scrme model administered 
heparin at 200 u/kg. Our study suggests that r-hirudin may 
be an effective anticoagulant for use in CPB. Since this 
agent does not produce any adverse effect on platelets and 
may not require neutralization, it may prove to be a 
superior anticoagulant for CPB. 
THE USE OF A NEW 
VENTRICULAR FAILURE 
CENTRIFUGAL PUMP IN POST-CARDIOTOMY 
Jack Curtis, M.D., F.A.C.C.) Joseph Walls, M.D. It 
F.A.C.C., Richard Schmaltz, M.D., Theresa Boley, R.N. 
University of Missouri-Columbia, Columbia, Missouri. 
Little has been published on the use of the Sarns 
centrifugal pump for cardiac assist. During a 25-month 
period ending November, 1988, we had experience with 40 
Sarns pumps in 27 patients (pts) who could not be weaned 
from cardiopulmonary bypass (CPB) In spite of maximal 
pharmacology and intra-aortic balloon support. Eighteen 
males and nine females with a mean age of 60.4 years (280 
83) required assist. Eighteen pts had isolated coronary 
artery bypasa grafting (CABG) (4 reoperations), one 
isolated valve repair (reoperation), three CAEG and valve 
repair, four CABG and left ventricular aneurysm 
resection, and one pulmonary thrombectomy. Preoperative 
ejection fraction ranged from 26-68% (mean 49.8). Cross- 
clamp times ranged from 18-126 minutes (median 69) with 
CPB times of 46-263 minutes (median 170). Left 
ventricular assist was used in 12 pts, right assist in 
twoI and biventricular assist In 13. The duration of 
assiet ranged from 2-434 hrs (median 45). The device was 
successful in weaning 100x of the Pts from 
cardiopulmonary bypass. Ten of 27 (37%) improved 
hemodynamically allowing removal of the device(s) and 
five of 27 (18.5X) survived hospitalization. Survival of 
pts with iso VB 8LF a3s as 33.3% (4 of 
12). All rie t lea e complication 
Including renal failure, hemorrhage, coagulopathy, 
ventricular dysrhythmias, sepsis D cerebral vascular 
accident, and wound infection. 
pump hours, 
During 3,560 centrifugal 
no pump thrombosis was observed. The Sarne 
centrifuga: pump is an effective assist device when used 
to salvage pts who are otherwise unweanable from CPB. 
